重症肺结核诊断和治疗专家共识
中华医学会结核病学分会组织专家制定重症肺结核诊断和治疗专家共识,围绕12个方面形成19条推荐意见。共识明确了重症肺结核的定义、三型分型及诊断标准,识别高危因素,并对治疗、药物相互作用、糖皮质激素使用、营养支持、大咯血处理、循环与器官支持、呼吸支持及康复等给出推荐,旨在提高诊疗科学性和规范性。
要点
- 重症肺结核指严重肺组织损伤或功能不全伴严重低氧血症,伴或不伴严重并发症。
- 分为严重肺组织损伤型、严重并发症型、危重症型三型,各有诊断标准。
- 强调尽早启动抗结核治疗,基于标准化方案个体化选药,关注药物相互作用及器官功能。
核心结论
- 共识形成19条推荐意见,为重症肺结核诊疗提供决策依据,以提高科学性和规范性。
研究设计与样本
- 中华医学会结核病学分会组织国内专家制定专家共识,涵盖12个方面共19条推荐意见。
主要发现
- 重症肺结核预后差、病死率高。
- 高危因素包括糖尿病、高龄、营养不良、免疫抑制状态、肾功能不全、耐多药结核病(1,B)。
- 分三型:严重肺组织损伤型、严重并发症型、危重症型(2,C)。
关键数值与推荐
- 严重肺组织损伤型需满足:病变范围≤2个肺野伴干酪性实变、空洞坏死等,或≥3个肺野,或气管狭窄;且氧合指数≤300 mmHg或动脉血氧分压≤60 mmHg(2,C)。
- 严重并发症型需满足:肺结核伴任一严重并发症(中心气道狭窄、大咯血、张力性气胸、呼吸频率≥30次/分、心力衰竭、肝衰竭、肾衰竭、意识障碍和/或定向障碍),同时氧合指数≤300 mmHg或动脉血氧分压≤60 mmHg(2,C)。
- 危重症型:肺结核伴休克或多器官衰竭需入ICU行呼吸、循环或其他器官支持(2,C)。
- 合并HIV的重症肺结核患者应在启动抗结核治疗2周内尽快开始抗逆转录病毒治疗(1,B)。
- 合并急性呼吸窘迫综合征(ARDS)者,在抗结核治疗有效前提下可给予糖皮质激素辅助治疗(1,B)。
临床怎么用
- 尽早启动抗结核治疗,基于标准化方案依据病情选用高效、低毒二线药物,并根据器官功能选药(2,B)。
- 合并胃肠道功能障碍者早期静脉滴注抗结核药物,病情稳定后逐渐过渡到口服(2,C)。
- 关注抗结核药物与抗真菌药物、抗逆转录病毒药物的相互作用,合理选药(1,B)。
- 对重症肺结核患者行营养风险筛查,血流动力学稳定者早期肠内营养可改善预后、降低病死率(1,B)。
- 合并大咯血者快速解除气道梗阻并保证氧供,稳定后行CT血管造影,必要时血管介入或手术(1,C)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with pulmonary tuberculosis (PTB) progressing severe conditions have a poor prognosis and high mortality. To enhance the scientificity and standardization of the diagnosis and treatment of severe PTB, the Chinese Society of Tuberculosis of Chinese Medical Association organized domestic experts to formulate the "Expert Consensus on the Diagnosis and Treatment of Severe Pulmonary Tuberculosis". The consensus presents 19 recommendation statements across the following 12 aspects, aiming to provide a decision-making basis for improving the management of severe PTB.The recommendations are listed below:Recommendation 1: Severe pulmonary tuberculosis refers to PTB accompanied with severe pulmonary parenchymal damage or functional impairment with severe hypoxemia, with or without serious complications (2, C).Recommendation 2: Based on clinical characteristics, severe PTB can be classified into the following three types, with diagnostic criteria as follows:Type Ⅰ: Severe Pulmonary Parenchymal Damage Type: Both of the following criteria must be met: (1) PTB lesion extent involving ≤2 lung fields accompanied by caseous consolidation, cavitary necrosis, etc., OR lesion extent involving ≥3 lung fields, OR tracheal stenosis; (2) Oxygenation index (PaO2/FiO2)≤300 mmHg or arterial partial pressure of oxygen (PaO2)≤60 mmHg (1 mmHg=0.133 kPa).Type Ⅱ: Severe Complication Type: PTB with any one of the following severe complications, concurrently with PaO2/FiO2≤300 mmHg or PaO2≤60 mmHg: (1) Central airway stenosis; (2) Massive hemoptysis; (3) Tension pneumothorax; (4) Respiratory rate ≥30 breaths/min; (5) Heart failure; (6) Liver failure; (7) Renal failure; (8) Impaired consciousness and/or disorientation.Type Ⅲ: Critical Illness Type: PTB with shock or multiple organ failure requiring admission to the ICU for respiratory, circulatory, or other organ support (2, C).Recommendation 3: Diabetes mellitus, advanced age, malnutrition, immunosuppressed status, renal insufficiency, and multidrug-resistant tuberculosis (MDR-TB) are high-risk factors for severe PTB (1, B).Recommendation 4: The anti-tuberculosis treatment for severe PTB follows the principles of early, combined, regular, adequate, full-course, and individualized therapy. Based on standardized first-line regimens, high-efficacy, low-toxicity second-line anti-TB drugs may be selected based on the patient's specific condition (2, B).Recommendation 5: For patients with severe PTB, it is recommended to initiate anti-TB treatment as early as possible when the clinical condition permits. Drug selection should be appropriate based on the patient's organ function (2, B).Recommendation 6: For severe PTB patients complicated with gastrointestinal dysfunction, it is recommended to initiate intravenous administration of anti-TB drugs early to rapidly achieve and maintain therapeutic blood drug levels, transitioning to oral administration gradually once the condition stabilizes (2, C).Recommendation 7: Interactions exist between anti-TB drugs and various antifungal agents. It is recommended to select anti-TB and antifungal drugs based on the patient's condition and the type of drug interactions (1, B).Recommendation 8: For severe PTB patients with HIV infection, antiretroviral therapy (ART) should be initiated as soon as possible, preferably within 2 weeks of initiating anti-TB treatment. The selection of anti-TB and antiretroviral drugs should be based on the patient's condition and drug interactions (1, B).Recommendation 9: For severe PTB patients with acute respiratory distress syndrome (ARDS), corticosteroid adjuvant therapy may be administered, under the premise of effective anti-tuberculosis treatment(1, B).Recommendation 10: Nutritional risk screening is recommended for patients with severe PTB. Early enteral nutrition for hemodynamically stable patients can improve prognosis and reduce mortality (1, B).Recommendation 11: For severe PTB patients with massive hemoptysis, rapid relief of airway obstruction and ensuring oxygen delivery are mandatory. After stabilization, computed tomography angiography (CTA) of the chest should be performed. Vascular interventional therapy or surgical intervention should be considered if necessary (1, C).Recommendation 12: For severe PTB patients with circulatory dysfunction, non-invasive/invasive hemodynamic monitoring should be performed, accompanied by fluid resuscitation and vasoactive drug support therapy (1, B).Recommendation 13: For patients with septic shock, early initiation of cytokine adsorption therapy is suggested (2, C).Recommendation 14: For severe PTB patients with severe renal failure, renal replacement therapy should be considered (2, B).Recommendation 15: For severe PTB patients with hepatic injury, close monitoring is essential. Drugs with a high incidence of hepatotoxicity should be discontinued, and comprehensive treatment including hepatoprotective therapy and supportive care should be provided (2, B).Recommendation 16: For severe PTB patients with respiratory failure, personalized respiratory support modalities is recommended (1, B).Recommendation 17: Attention must be paid to infection control management related to high-risk respiratory therapy operations for severe PTB patients (2, C).Recommendation 18: Extracorporeal membrane oxygenation (ECMO) therapy can be considered for severe PTB patients with ARDS (2, C).Recommendation 19: Early rehabilitation therapy is recommended for severe PTB patients. Safety assessment should be conducted prior to rehabilitation, with real-time monitoring of vital signs and rehabilitation should be terminated promptly if necessary(2, B). 肺结核患者进展为重症后预后差、病死率高,为提高重症肺结核诊疗的科学性和规范性,中华医学会结核病学分会组织国内相关专家制订了《重症肺结核诊断和治疗专家共识》。本共识在以下12方面共形成19条推荐意见,希望为提高重症肺结核诊疗的科学性和规范性提供决策依据。(1)重症肺结核定义:重症肺结核是指出现严重的肺组织损伤或功能不全伴严重低氧血症,伴或不伴严重并发症的肺结核。(2)重症肺结核分型:分为严重肺组织损伤型、严重并发症型、危重症型三型。(3)重症肺结核高危因素:糖尿病、高龄、营养不良、免疫抑制状态、肾功能不全、耐多药结核病。(4)重症肺结核的治疗:强调尽早启动抗结核治疗,在标准化方案基础上可依据患者的具体病情选用高效、低毒二线药物,需关注合并脓毒性休克者药代动力学和药效学的变化,建议对合并胃肠道功能障碍者早期给予静脉滴注抗结核药物治疗;(5)药物相互作用:多种抗结核药物是CYP3A4的诱导剂或抑制剂,可与多种抗真菌药物、抗逆转录病毒药物间存在相互作用导致药物活性和浓度的改变,可能诱发严重的不良反应,强调合理用药;合并HIV的重症肺结核患者在启动抗结核治疗2周内需尽快开始抗逆转录病毒治疗,疗程至少与HIV阴性患者相同,推荐固定复合剂量给药;(6)糖皮质激素的使用:对于合并急性呼吸窘迫综合征(ARDS)的重症肺结核患者,在抗结核治疗有效的前提下可给予糖皮质激素辅助治疗;(7)重症肺结核的营养支持治疗:需对重症肺结核患者行营养筛查,危重症患者早期采用允许性低热量营养策略,治疗中需遵循五阶梯治疗原则,推荐对无肠内营养禁忌证并且血流动力学稳定的重症肺结核患者早期进行肠内营养;(8)大咯血的处理:对于重症肺结核合并大咯血者,必须快速解除呼吸道梗阻,保证氧气吸入,待病情稳定后完善CT血管造影检查,行血管介入或外科手术治疗。(9)循环支持治疗:对重症肺结核合并循环功能障碍者可早期给予晶体液复苏及血管活性药物支持,对合并脓毒症休克者建议早期启动细胞因子吸附治疗;(10)肝脏、肾脏支持治疗:重症肺结核患者肝损伤风险高,根据肝损伤程度给予对症支持治疗;合并肾功能不全时可行肾脏替代治疗;(11)呼吸支持治疗及院感防控:重症肺结核导致呼吸衰竭时推荐实施个性化的呼吸支持方式,同时需注意呼吸治疗相关高风险操作的感控管理,对于合并重度ARDS的重症肺结核患者可采用体外膜氧合治疗;(12)康复治疗:对于重症肺结核患者建议实施早期康复治疗,康复前进行安全性评估,实时监测生命体征变化,必要时及时中止。.
引用
- [Expert consensus on the diagnosis and treatment of severe pulmonary tuberculosis]. Zhonghua Jie He He Hu Xi Za Zhi. 2025. PMID: 41362141. doi:10.3760/cma.j.cn112147-20250722-00429
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。